Tumor cells in pleural effusion and peripheral blood of malignant pleural mesothelioma patients

Tumor cells in pleural effusion and peripheral blood of malignant pleural mesothelioma patients - MESOPA

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON40425

Enrollment

Registered

2014-04-24

Start date

2014-06-04

Completion date

Unknown

Last updated

2024-06-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

maligant pleural mesothelioma malignant mesothelioma

Interventions

In all patients, except in the control patients, 3x10 mL of peripheral blood will be drawn for circulating tumor cell (CTC), circulating endothelial cell (CEC) and immune cell analysis.

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: - Age >

Exclusion criteria

Exclusion criteria: None

Design outcomes

Primary

Measure	Time frame
Verdict of pleural effusion analysis (negative for MPM, suspicious for MPM or positive for MPM) by PTC enumeration versus cytological analysis.	—

Secondary

Measure	Time frame
- Number of CTCs - Number of CECs - Number of immune cells - Overall survival	—

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)